Randomized phase III trial of adjuvant chemotherapy with gemcitabine vs S-1 in patients with resected pancreatic cancer.

Trial Profile

Randomized phase III trial of adjuvant chemotherapy with gemcitabine vs S-1 in patients with resected pancreatic cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2018 Results (n=354) assessing health-related quality of life with of S-1 versus gemcitabine in patients with pancreatic cancer published in the European Journal of Cancer.
    • 02 Jun 2016 Results published in The Lancet.
    • 02 Jun 2016 Status changed from active, no longer recruiting to completed, as per an article published in The Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top